A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysisПодробнее

The evolution of HER2-low breast cancer from primary to recurrenceПодробнее

The Science of HER2-low Breast Cancer and Implications for the Pathology TeamПодробнее

Questions remaining in the field of HER2-low breast cancerПодробнее

New Perspectives on the Full Spectrum of HER2 Expression in Breast CancerПодробнее

HER2-low expression in breast cancerПодробнее

The significance of HER2 expression for the activity of trastuzumab deruxtecanПодробнее

HER2 Testing in Breast Cancer: Improving IHC PerformanceПодробнее

Overview of the management of HER2-low breast cancer patientsПодробнее

Biological behaviour of HER2-low BC is dependent on HR expressionПодробнее

Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancerПодробнее

Role of HER2 expression and pCR in predicting early outcomes in HER2-positive breast cancerПодробнее

Remaining questions on the management of HER2-low breast cancerПодробнее

Treatement of HER2 Low Breast CancerПодробнее

#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024Подробнее

HER2 Low Breast Cancer A New Therapeutic Subtype | 2023 KU Breast Cancer Year in Review ConferenceПодробнее

Highlights in HER2-low breast cancer at SABCS 2022Подробнее

Remaining questions regarding HER2-low breast cancerПодробнее

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markersПодробнее

Is HER2-low a distinct subtype of breast cancer?Подробнее